Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | Tandutinib |
Synonyms | |
Therapy Description |
Tandutinib (CT53518) is a tyrosine kinase inhibitor of FLT3, KIT, and PDGFRbeta, which inhibits cell proliferation and induces apoptosis (PMID: 12166950, PMID: 12124172, PMID: 27663390). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Tandutinib | MLN518|CT53518|CT-53518|MLN-518 | FLT3 Inhibitor 66 KIT Inhibitor 57 PDGFR-beta Inhibitor 14 | Tandutinib (CT53518) is a tyrosine kinase inhibitor of FLT3, KIT, and PDGFRbeta, which inhibits cell proliferation and induces apoptosis (PMID: 12166950, PMID: 12124172, PMID: 27663390). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
FLT3 Y599_D600insGLYVDFREYEY | acute myeloid leukemia | sensitive | Tandutinib | Preclinical | Actionable | In a preclinical study, tandutinib (CT53518) inhibited proliferation of cells expressing FLT3 Y599_D600insGLYVDFREYEY in culture (PMID: 12124172). | 12124172 |
FLT3 R595_L601dup | acute myeloid leukemia | sensitive | Tandutinib | Preclinical | Actionable | In a preclinical study, tandutinib (CT53518) inhibited cell proliferation in cell culture and in mouse models carrying FLT3 L601_K602insREYEYDL (PMID: 12124172). | 12124172 |
FLT3 exon 14 ins | acute myeloid leukemia | sensitive | Tandutinib | Preclinical - Cell culture | Actionable | In a preclinical study, Tandutinib (CT53518) treatment inhibited viability of an acute myeloid leukemia cell line harboring FLT3 internal tandem duplication (ITD) in culture (PMID: 31751472). | 31751472 |
FLT3 E598_Y599insGLVQVTGSSDNEYFYVDFREYE | acute myeloid leukemia | sensitive | Tandutinib | Preclinical | Actionable | In a preclinical study, tandutinib (CT53518) inhibited proliferation of cells expressing FLT3 E598_Y599insGLVQVTGSSDNEYFYVDFREYE in culture (PMID: 12124172). | 12124172 |
FLT3 I836del | cancer | sensitive | Tandutinib | Preclinical - Cell culture | Actionable | In a preclinical study, Tandutinib (CT53518) inhibited phosphorylation of FLT3 and activation of ERK and STAT5, and reduced growth of transformed cells expressing FLT3 I836del in culture (PMID: 15256420). | 15256420 |
FLT3 G613_K614insYVDFREYEYDLKWEFRPRENLEFG | acute myeloid leukemia | sensitive | Tandutinib | Preclinical - Cell culture | Actionable | In a preclinical study, Tandutinib (CT53518) inhibited proliferation of cells expressing FLT3 G613_K614insYVDFREYEYDLKWEFRPRENLEFG in culture (PMID: 12124172). | 12124172 |
FLT3 exon 14 ins FLT3 D835Y | acute myeloid leukemia | resistant | Tandutinib | Preclinical - Cell culture | Actionable | In a preclinical study, an acute myeloid cell line harboring FLT3 internal tandem duplication (ITD) and FLT3 D835Y demonstrated resistance to Tandutinib (CT53518) treatment in culture (PMID: 31751472). | 31751472 |
FLT3 L610_E611insCSSDNEYFYVDFREYEYDLKWEFPRENL | acute myeloid leukemia | sensitive | Tandutinib | Preclinical - Cell culture | Actionable | In a preclinical study, tandutinib (CT53518) inhibited proliferation of cells expressing FLT3 L610_E611insCSSDNEYFYVDFREYEYDLKWEFPRENL in culture (PMID: 12124172). | 12124172 |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|